Helping investors discover, understand, and stay up-to-date on opportunities within the Psychedelic industry. Inquiries: hello@psychedelicfinance.com
Canada
- Tweets 4,310
- Following 154
- Followers 20,809
- Likes 1,451
Pinned Tweet
Welcome to Psychedelic Finance.
We exist to help bridge the gap between the exciting world of psychedelic medicine and the companies being built around it.
If you'd like to see our more detailed research on the industry, you can join the community here:
psychedelicfinance.com/
31
36
136
Breaking: $PBM agrees to invest up to $5 million in PsyLabs, including $2.4 million committed, plus a roughly $9 million share swap to support a potential Texas trial of ibogaine for opioid use disorder.
2
678
Breaking: $ENVB receives its third U.S. patent allowance for EVM401, covering non-hallucinogenic mescaline-derived drug candidates for potential PTSD and other mental health treatments.
1
731
Breaking: $PBM forms Texas Ibogaine Research Corp. to coordinate U.S. drug supply, regulatory work and potential clinical development.
3
813
Breaking: $DFTX receives FDA Breakthrough Therapy designation for DT120 in major depression after a positive Phase 3 trial showed durable improvement through Week 12.
12
865
Psychedelic Finance retweeted
Breaking: $DFTX receives FDA Breakthrough Therapy designation for DT120 in major depression after a positive Phase 3 trial showed durable improvement through Week 12.
1
7
1,081
Psychedelic Finance retweeted
Breaking: $HELP completes enrollment in its Phase 3 HLP003 depression trial with topline data expected in Q4, while Q1 net loss widens to $47.8 million and cash stands at $166.4 million.
2
9
761
Psychedelic Finance retweeted
Breaking: Compass Pathways has partnered with the U.S. Department of Veterans Affairs for a new psilocybin study.
$CMPS $ATAI $LLY
thenew.money/article/compass…
3
6
781
Psychedelic Finance retweeted
Breaking: $CMPS partners with the U.S. Department of Veterans Affairs on a five-site trial of COMP360 psilocybin for veterans with treatment-resistant depression, including those with PTSD.
2
4
13
828
Psychedelic Finance retweeted
Breaking: Shares of psychedelic drug discovery company $HELP have surged +50% over the past month.
2
3
11
789
Psychedelic Finance retweeted
Breaking: $HELP completes 223-patient Phase 3 enrollment for depression drug HLP003 ahead of schedule, with topline data due Q4 2026.
1
2
12
566
Psychedelic Finance retweeted
Eli Lilly has entered into a new deal to acquire AtaiBeckley for up to $3.5 billion in the drugmaker’s first ever psychedelic drug discovery acquisition.
$ATAI $LLY @C_Angermayer
thenew.money/article/eli-lil…
5
8
947
Psychedelic Finance retweeted
Definium Therapeutics has just completed a massive new capital raise.
And they are aiming to use it to bring their most advanced psychedelic derived drug into commercialization.
$DFTX
thenew.money/article/definiu…
1
10
796
Psychedelic Finance retweeted
Breaking: $CMND completes treatment of all 24 participants across four cohorts in Part A of its FDA-regulated Phase I/II CMND-100 trial for alcohol use disorder and will review the data before advancing to the next stage.
1
6
529
Psychedelic Finance retweeted
A publicly traded company on the Nasdaq is shipping psilocybin to the United Kingdom. But, why?
$OPTH
thenew.money/article/optimi-…
1
2
5
380
Psychedelic Finance retweeted
Breaking: $OPTH completes its first export of naturally derived psilocybin to the United Kingdom, supplying biomass and finished 5mg capsules for a planned Phase 2 clinical trial under Health Canada and UK Home Office authorization.
1
1
4
328
Psychedelic Finance retweeted
Breaking: $TELIF signs an agreement to deploy its third Self-Driving Lab platform of fiscal 2026 for a major global pharmaceutical company in Europe.
1
5
406
Psychedelic Finance retweeted
Breaking: $ATAI launches a Patient Impact Grant Program awarding three $20,000 grants to mental health non-profits focused on community support, education, stigma reduction and independent research.
3
10
428
Psychedelic Finance retweeted
Breaking: $CMPS reports Q1 2026 results with cash and cash equivalents of ~$216M, providing runway into 2027 as it advances late-stage COMP360 psilocybin trials toward potential commercialization for treatment-resistant depression.
2
2
11
832
Psychedelic Finance retweeted
Psychedelic medicines are getting a big boost of support from the White House.
And it might be just the beginning of reshaping the future of psychedelic drugs in America.
thenew.money/article/theres-…
2
6
15
713